3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
6
Not yet recruiting
3
Recruiting
2
Withdrawn
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
12
Neoplasm Metastasis
3
Myelodysplastic Syndromes
3
Melanoma
3
Leukemia, Myelomonocytic, Chronic
3
Breast Neoplasms
3
Advanced Solid Tumor
3
Recurrence
2
Ovarian Neoplasms
2
Lymphoma, B-Cell
2
Leukemia, Monocytic, Acute
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Papillomavirus Infections
1
Non-Squamous Non-small Cell Lung Cancer
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Multiple Myeloma
1
Microsatellite Instability
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Radiotherapy
11
pembrolizumab
10
Nivolumab
10
Doxorubicin
10
Magnetic Resonance Spectroscopy
9
Specimen Handling
8
Ipilimumab
7
Cyclophosphamide
7
Biopsy
7
X-Rays
6
Radiation
5
Phantoms, Imaging
5
Ifosfamide
5
talimogene laherparepvec
4
cabozantinib
4
Nuclear Medicine Department, Hospital
4
Irinotecan
4
tazemetostat
3
selpercatinib
3
pazopanib
3
liposomal doxorubicin
3
Temozolomide
3
Etoposide
3
ulixertinib
2
tislelizumab
2
tipifarnib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Sarcoma
×
Injections
×
Clear all
NCT05688280
2025-01-08
INJECTABL-1
Immunophotonics, Inc.
Phase 1/2
Active not recruiting
42 enrolled